$SER
Serina Therapeutics Inc Stock $ser

$ser Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000149315223028478 Filed on August 14, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$67.00K	$9.000K	$12.00K
YoY Change	644.44%	-25.0%	-67.57%
Cost Of Revenue	$33.00K	$5.000K	$6.000K
YoY Change	560.0%	-16.67%	-53.85%
Gross Profit	$34.00K	$4.000K	$6.000K
YoY Change	750.0%	-33.33%	-75.0%
Gross Profit Margin	50.75%	44.44%	50.0%
Selling, General & Admin	$2.170M	$1.730M	$1.338M
YoY Change	55.89%	29.3%	-23.46%
% of Gross Profit	6382.35%	43250.0%	22300.0%
Research & Development	$218.0K	$160.0K	$259.0K
YoY Change	34.57%	-38.22%	-46.15%
% of Gross Profit	641.18%	4000.0%	4316.67%
Depreciation & Amortization	$30.00K	$32.00K	$33.00K
YoY Change	-9.09%	-3.03%	0.0%
% of Gross Profit	88.24%	800.0%	550.0%
Operating Expenses	$2.390M	$1.890M	$1.597M
YoY Change	53.8%	18.35%	-28.35%
Operating Profit	-$2.356M	-$1.886M	-$1.591M
YoY Change	52.0%	18.54%	-27.85%
Interest Expense	$3.036M	$792.0K	-$863.0K
YoY Change	228.93%	-191.77%	214.96%
% of Operating Profit
Other Income/Expense, Net	-$3.033M	-$793.0K	-$1.027M
YoY Change	242.33%	-22.78%	280.37%
Pretax Income	-$5.390M	-$2.679M	-$2.618M
YoY Change	121.26%	2.33%	5.78%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$5.401M	-$2.669M	-$2.618M
YoY Change	121.81%	1.95%	5.82%
Net Earnings / Revenue	-8061.19%	-29655.56%	-21816.67%
Basic Earnings Per Share	-$0.14	-$0.07	-$0.07
Diluted Earnings Per Share	-$0.14	-$0.07	-$69.00K
COMMON SHARES
Basic Shares Outstanding	37.95M shares	37.95M shares	37.94K shares
Diluted Shares Outstanding	37.95K shares	37.95K shares	37.94K shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$400.0K	$261.0K	$702.0K
YoY Change	-14.16%	-62.82%	14.15%
Cash & Equivalents	$397.0K	$261.0K	$702.0K
Short-Term Investments
Other Short-Term Assets	$670.0K	$1.083M	$1.011M
YoY Change	-6.94%	7.12%	8.71%
Inventory
Prepaid Expenses
Receivables	$67.00K	$6.000K	$12.00K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.141M	$1.350M	$1.725M
YoY Change	-3.88%	-21.74%	10.86%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles	$640.0K	$673.0K	$804.0K
YoY Change	-16.99%	-16.29%
Long-Term Investments
YoY Change
Other Assets	$50.00K	$50.00K	$50.00K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$11.07M	$10.93M	$854.0K
YoY Change	1248.23%	1179.51%	-13.3%
TOTAL ASSETS
Total Short-Term Assets	$1.141M	$1.350M	$1.725M
Total Long-Term Assets	$11.07M	$10.93M	$854.0K
Total Assets	$12.21M	$12.28M	$2.579M
YoY Change	508.07%	376.04%	1.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.172M	$506.0K	$161.0K
YoY Change	233.9%	214.29%	-66.67%
Accrued Expenses	$293.0K	$256.0K	$521.0K
YoY Change	-33.56%	-50.86%	-36.39%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.530M	$22.94M	$6.968M
YoY Change	-79.04%	229.26%	95.73%
Total Short-Term Liabilities	$3.204M	$24.51M	$9.085M
YoY Change	-63.63%	169.73%	72.36%
LONG-TERM LIABILITIES
Long-Term Debt	$690.0K	$10.07M	$6.756M
YoY Change	-91.73%	49.02%	21.42%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$690.0K	$10.07M	$6.756M
YoY Change	-91.73%	49.02%	21.42%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.204M	$24.51M	$9.085M
Total Long-Term Liabilities	$690.0K	$10.07M	$6.756M
Total Liabilities	$3.897M	$34.57M	$15.84M
YoY Change	-77.29%	118.25%	46.77%
SHAREHOLDERS EQUITY
Retained Earnings	-$127.6M	-$122.2M	-$111.1M
YoY Change	12.39%	10.02%
Common Stock	$4.000K	$4.000K	$4.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$27.54M	-$22.18M	-$13.22M
YoY Change
Total Liabilities & Shareholders Equity	$12.21M	$12.28M	$2.579M
YoY Change	508.07%	376.04%	1.5%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$5.401M	-$2.669M	-$2.618M
YoY Change	121.81%	1.95%	5.82%
Depreciation, Depletion And Amortization	$30.00K	$32.00K	$33.00K
YoY Change	-9.09%	-3.03%	0.0%
Cash From Operating Activities	-$1.870M	-$2.019M	-$1.746M
YoY Change	51.29%	15.64%	3.07%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change
Cash From Investing Activities	$0.00	$0.00	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.000M	2.000M	2.000M
YoY Change	100.0%	0.0%	33.33%
NET CHANGE
Cash From Operating Activities	-1.870M	-2.019M	-1.746M
Cash From Investing Activities	0.000	0.000	0.000
Cash From Financing Activities	2.000M	2.000M	2.000M
Net Change In Cash	130.0K	-19.00K	254.0K
YoY Change	-155.08%	-107.48%	-230.93%
FREE CASH FLOW
Cash From Operating Activities	-$1.870M	-$2.019M	-$1.746M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001708599
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q4	us-gaap	Notes And Loans Receivable Gross Noncurrent NotesAndLoansReceivableGrossNoncurrent		usd
CY2023Q2	AGE	Warrant Liability WarrantLiability		usd
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
CY2022Q2	AGE	Less Comprehensive Loss Attributable To Noncontrolling Interest From Continuing Operations LessComprehensiveLossAttributableToNoncontrollingInterestFromContinuingOperations		usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables		usd
	AGE	Cash Advanced On Convertible Note Receivable CashAdvancedOnConvertibleNoteReceivable		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2021Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding		usd
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding		shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
CY2021Q4	AGE	Warrant Liability WarrantLiability		usd
CY2022	AGE	Unrealized Loss On Change In Fair Value Of Warrants UnrealizedLossOnChangeInFairValueOfWarrants		usd
CY2022	AGE	Unrealized Loss On Change On Other Than Options UnrealizedLossOnChangeOnOtherThanOptions		shares
CY2022	AGE	Unrealized Loss On Change In Fair Value Of Warrants Per Share UnrealizedLossOnChangeInFairValueOfWarrantsPerShare
	AGE	Unrealized Loss On Change In Fair Value Of Warrants UnrealizedLossOnChangeInFairValueOfWarrants		usd
	AGE	Unrealized Loss On Change On Other Than Options UnrealizedLossOnChangeOnOtherThanOptions		shares
	AGE	Unrealized Loss On Change In Fair Value Of Warrants Per Share UnrealizedLossOnChangeInFairValueOfWarrantsPerShare
CY2023Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding		usd
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding		shares
CY2023Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
CY2023Q2	AGE	Warrant Liability WarrantLiability		usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2023Q2	us-gaap	Accelerated Share Repurchases Final Price Paid Per Share AcceleratedShareRepurchasesFinalPricePaidPerShare
	us-gaap	Accelerated Share Repurchases Final Price Paid Per Share AcceleratedShareRepurchasesFinalPricePaidPerShare
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate		pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate		pure
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate		pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate		pure
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
	us-gaap	Short Term Debt Refinanced Amount ShortTermDebtRefinancedAmount		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	1-38519
	dei	Entity Registrant Name EntityRegistrantName	AgeX Therapeutics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-1436829
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1101 Marina Village Parkway
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 201
	dei	Entity Address City Or Town EntityAddressCityOrTown	Alameda
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94501
	dei	City Area Code CityAreaCode	(510)
	dei	Local Phone Number LocalPhoneNumber	671-8370
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	AGE
	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	37951261	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	261000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	645000	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1083000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1804000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	1350000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	2453000	usd
CY2023Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	50000	usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	50000	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	673000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	738000	usd
CY2023Q2	us-gaap	Notes And Loans Receivable Gross Noncurrent NotesAndLoansReceivableGrossNoncurrent	10204000	usd
CY2023Q2	us-gaap	Assets Assets	12277000	usd
CY2022Q4	us-gaap	Assets Assets	3241000	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	961000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1034000	usd
CY2023Q2	us-gaap	Loans Payable Current LoansPayableCurrent	22943000	usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent	7646000	usd
CY2022Q4	AGE	Warrant Liability WarrantLiability	180000	usd
CY2023Q2	AGE	Insurance Premium Liability And Other Current Liabilities InsurancePremiumLiabilityAndOtherCurrentLiabilities	371000	usd
CY2022Q4	AGE	Insurance Premium Liability And Other Current Liabilities InsurancePremiumLiabilityAndOtherCurrentLiabilities	1077000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	24505000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10078000	usd
CY2023Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	10068000	usd
CY2022Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	10478000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	34573000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	20556000	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37951000	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37951000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37949000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37949000	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	99977000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	98994000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-122156000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-116210000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-22175000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-17212000	usd
CY2023Q2	us-gaap	Minority Interest MinorityInterest	-121000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-103000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-22296000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-17315000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12277000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3241000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	19000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	17000	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	5000	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	6000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	6000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	7000	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	4000	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	6000	usd
	us-gaap	Gross Profit GrossProfit	13000	usd
	us-gaap	Gross Profit GrossProfit	10000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	160000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	259000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	334000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	655000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1730000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1338000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3723000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2998000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	1890000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	1597000	usd
	us-gaap	Operating Expenses OperatingExpenses	4057000	usd
	us-gaap	Operating Expenses OperatingExpenses	3653000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1886000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1591000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4044000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3643000	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	792000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	863000	usd
	us-gaap	Interest Expense InterestExpense	1892000	usd
	us-gaap	Interest Expense InterestExpense	1434000	usd
CY2023Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	5000	usd
CY2022Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	168000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	35000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	255000	usd
CY2023Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	4000	usd
CY2022Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	4000	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	7000	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	7000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-793000	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1027000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1920000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1682000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-2679000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-2618000	usd
	us-gaap	Profit Loss ProfitLoss	-5964000	usd
	us-gaap	Profit Loss ProfitLoss	-5325000	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-10000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-18000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2669000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2618000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5946000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5324000	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37951	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37951	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37943	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37943	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37950	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37950	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37943	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37943	shares
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-2679000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-2618000	usd
	us-gaap	Profit Loss ProfitLoss	-5964000	usd
	us-gaap	Profit Loss ProfitLoss	-5325000	usd
CY2023Q2	AGE	Less Comprehensive Loss Attributable To Noncontrolling Interest From Continuing Operations LessComprehensiveLossAttributableToNoncontrollingInterestFromContinuingOperations	10000	usd
	AGE	Less Comprehensive Loss Attributable To Noncontrolling Interest From Continuing Operations LessComprehensiveLossAttributableToNoncontrollingInterestFromContinuingOperations	18000	usd
	AGE	Less Comprehensive Loss Attributable To Noncontrolling Interest From Continuing Operations LessComprehensiveLossAttributableToNoncontrollingInterestFromContinuingOperations	1000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-2669000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-2618000	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-5946000	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-5324000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-20005000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	353000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	35000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-2679000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-22296000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-22296000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-11591000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-1000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	750000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	198000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-2618000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-13262000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-13262000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-17315000	usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-1000	usd
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	879000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	105000	usd
	us-gaap	Profit Loss ProfitLoss	-5964000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-22296000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-22296000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-11875000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-11875000	usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-2000	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	178000	usd
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	3325000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	437000	usd
	us-gaap	Profit Loss ProfitLoss	-5325000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-13262000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-13262000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5946000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5324000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-18000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	35000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	255000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	65000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	66000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1976000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1355000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	105000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	437000	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	2000	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-13000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-721000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-614000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	204000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-96000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-207000	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	186000	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	65000	usd
	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	-711000	usd
	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	-653000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	5000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-2000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3884000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3382000	usd
	AGE	Cash Advanced On Convertible Note Receivable CashAdvancedOnConvertibleNoteReceivable	10000000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10000000	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	13500000	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	3500000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13500000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3500000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-384000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	118000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	695000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	634000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	311000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	752000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-122200000	usd
CY2023Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	300000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84E_eus-gaap--UseOfEstimates_zYsz6xt4NrE3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_868_zfzEdaz2Nyoa">Use of estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and (ii) the reported amounts of revenues and expenses during the reporting period, in each case with consideration given to materiality. Significant estimates and assumptions which are subject to significant judgment include those related to going concern assessment of consolidated financial statements, useful lives associated with long-lived assets, including evaluation of asset impairment, allowances for uncollectible accounts receivables, loss contingencies, deferred income taxes and tax reserves, including valuation allowances related to deferred income taxes, determining the fair value of AgeX’s embedded derivatives in the convertible notes payable and receivable, and assumptions used to value stock-based awards or other equity instruments and liability classified warrants. Actual results could differ materially from those estimates. The financial information for private companies may not be available and, even if available, that information may be limited and/or unreliable. To the extent there are material differences between the estimates and actual results, AgeX’s future results of operations will be affected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 6, <i>Warrant Liability</i>, for discussion on estimated change in fair value of warrant liability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_zJKZnimvwIxj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zHHJd68tc7K5">Concentration of credit risk and other risks and uncertainties</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject AgeX to concentrations of risk consist principally of cash equivalents and a convertible note receivable. AgeX maintains its cash deposits in Federal Deposit Insurance Corporation insured financial institutions within the federally insured limits. Even if balances were to exceed the federally insured limits, AgeX does not believe that it would be exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AgeX also monitors the creditworthiness of the borrower of the convertible promissory note. AgeX believes that any concentration of credit risk in a convertible note receivable was mitigated in part by (i) AgeX’s right to convert loan amounts owed to AgeX into shares of equity securities of the borrower in the event the borrower completes a financing in at least a designated amount, and (ii) AgeX’s right to tender the convertible note receivable to a lender to settle a convertible note payable. See Notes 4, <i>Convertible Note Receivable </i>and 5, <i>Related Party Transactions</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product candidates developed by AgeX and its subsidiaries will require approvals or clearances from the United States Food and Drug Administration or foreign regulatory agencies prior to commercial sales. There can be no assurance that any of the product candidates being developed or planned to be developed by AgeX or its subsidiaries will receive any of the required approvals or clearances. If regulatory approval or clearance were to be denied or any such approval or clearance was to be delayed, it would have a material adverse impact on AgeX.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	(i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset.
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1034000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	261000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	645000	usd
CY2023Q2	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	50000	usd
CY2022Q4	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	50000	usd
CY2023Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	311000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	695000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P10Y
CY2023Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1312000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1312000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	639000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	574000	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	673000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	738000	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	32000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	65000	usd
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	33000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	66000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	66000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	131000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	131000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	132000	usd
CY2023Q2	AGE	Finite Lived Intangible Assets Amortization Expense After Year Three FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearThree	213000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	673000	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	506000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	568000	usd
CY2023Q2	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	199000	usd
CY2022Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	193000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	256000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	273000	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	961000	usd
CY2023Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	105000000	usd
CY2023Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.10	pure
CY2023Q1	us-gaap	Other Assets OtherAssets	250000	usd
	us-gaap	Line Of Credit Facility Expiration Date1 LineOfCreditFacilityExpirationDate1	2024-02-14
CY2023Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	10357086	shares
CY2023Q2	us-gaap	Common Stock Held By Subsidiary CommonStockHeldBySubsidiary	250000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	25000000	usd
CY2023Q1	AGE	Common Stock Outstanding Percentage CommonStockOutstandingPercentage	0.85	pure
CY2023Q2	us-gaap	Secured Debt SecuredDebt	10000000	usd
CY2023Q2	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	2000000000	usd
CY2022	AGE	Changes In Fair Value ChangesInFairValue	225000	usd
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	500000	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	454545	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.3960
CY2022Q4	AGE	Warrant Liability WarrantLiability	180000	usd
	AGE	Changes In Fair Value ChangesInFairValue	35000	usd
CY2023Q2	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	2000000000	usd
CY2023Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	5000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	35000	usd
CY2022Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	168000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	255000	usd
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37951261	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37951261	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37949196	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37949196	shares
CY2023Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8500000	shares
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	35000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	198000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	105000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	437000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.71
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.79
CY2022Q2	us-gaap	Accelerated Share Repurchases Final Price Paid Per Share AcceleratedShareRepurchasesFinalPricePaidPerShare	0.71
	us-gaap	Accelerated Share Repurchases Final Price Paid Per Share AcceleratedShareRepurchasesFinalPricePaidPerShare	0.79
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y29D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M29D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.2835	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.3071	pure
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0290	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0174	pure
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Interest Paid Net InterestPaidNet	23000	usd
	us-gaap	Interest Paid Net InterestPaidNet	12000	usd
	AGE	Issuance Of Common Stock Upon Vesting Of Restricted Stock Units IssuanceOfCommonStockUponVestingOfRestrictedStockUnits	2000	usd
	AGE	Issuance Of Common Stock Upon Vesting Of Restricted Stock Units IssuanceOfCommonStockUponVestingOfRestrictedStockUnits	5000	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	178000	usd
	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	663000	usd
	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	3325000	usd
	us-gaap	Short Term Debt Refinanced Amount ShortTermDebtRefinancedAmount	7160000	usd
	us-gaap	Preferred Stock Voting Rights PreferredStockVotingRights	(i) creation of any Preferred Stock ranking as senior stock to the series with respect to liquidation preferences; (ii) repurchase of any shares of common stock or other junior stock except shares issued pursuant to or in connection with a compensation or incentive plan or agreement approved by the Board of Directors for any officers, directors, employees or consultants of AgeX; (iii) any sale, conveyance, or other disposition of all or substantially all AgeX’s property or business, or any liquidation or dissolution of AgeX, or a merger into or consolidation with any other corporation (other than a wholly-owned subsidiary corporation) but only to the extent that the Delaware General Corporation Law requires that such transaction be approved by each class or series of Preferred Stock; (iv) any adverse change in the powers, preferences and rights of, and the qualifications, limitations or restrictions on, the series of Preferred Stock; or (v) any amendment of AgeX’s Certificate of Incorporation or Bylaws that results in any adverse change in the powers, preferences and rights of, and the qualifications, limitations or restrictions on, the series of Preferred Stock. However, the terms of the Preferred Stock do not restrict or limit the rights and powers of the Board of Directors to fix by resolution the rights, preferences, and privileges of, and restrictions and limitations on, stock ranking as parity stock or junior stock to a series of Preferred Stock.

Files In Submission

Name	View Source	Status
age-20230630_def.xml	Edgar Link	unprocessable
0001493152-23-028478-index-headers.html	Edgar Link	pending
0001493152-23-028478-index.html	Edgar Link	pending
0001493152-23-028478.txt	Edgar Link	pending
0001493152-23-028478-xbrl.zip	Edgar Link	pending
age-20230630.xsd	Edgar Link	pending
ex10-7.htm	Edgar Link	pending
ex10-8.htm	Edgar Link	pending
ex31.htm	Edgar Link	pending
ex32.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
age-20230630_lab.xml	Edgar Link	unprocessable
age-20230630_pre.xml	Edgar Link	unprocessable
age-20230630_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SER
Serina Therapeutics Inc Stock $ser

2023 Q3 Form 10-Q Financial Statement

#000149315223028478 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SER Serina Therapeutics Inc Stock $ser

2023 Q3 Form 10-Q Financial Statement

#000149315223028478 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SER
Serina Therapeutics Inc Stock $ser